AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

NCT03313557 | Completed Phase 1 FDA Drug

• 1 other identifier: D6014C00007
• Study Type: interventional
• Target: 48
• Locations: 4 countries
• Sites: 14

Brief Summary

Open-label, non-randomised study to provide continued access to AZD1775 for patients with advanced solid tumours who have previously completed an AZD1775 clinical pharmacology study and to investigate the safety of AZD1775.

Conditions

Solid Tumors

Keywords

Continued access, safety assessments

Outcome Measures

Primary Outcomes (6)

• Adverse Events, graded by the National Cancer Institute Common Terminology Criteria for Adverse Event's (CTCAE v4.3)

  To assess the safety of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours

  Until 30 days following the final dose of AZD1775

• Complete physical examination including performance status assessed using the Eastern Cooperative Oncology Group (ECOG) Performance Status criteria.

  To assess the safety and tolerability of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours. If new or aggravated physical findings imply deterioration compared with baseline, the finding will be reported as an Adverse Event, unless the findings are unequivocally due to disease progression.

  Until 30 days following the final dose of AZD1775

• Pulse Rate (beats/min)

  To assess the safety and tolerability of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours.

  Until 30 days following the final dose of AZD1775

• Blood Pressure (mm Hg)

  To assess the safety and tolerability of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours.

  Until 30 days following the final dose of AZD1775

• Body Temperature (°C)

  To assess the safety and tolerability of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours.

  Until 30 days following the final dose of AZD1775

• Evaluation of Laboratory Parameters

  To assess the safety and tolerability of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours; deterioration of haematology and clinical chemistry laboratory values as compared to baseline will be reported as Adverse Events if they fulfill any of the Serious Adverse Events criteria or are the reason for discontinuation of the study treatment unless clearly due to the progression of disease under study; if deterioration in a laboratory value is associated with clinical signs and symptoms, the sign or symptom will be reported as an AE and the associated laboratory result will be considered as additional information.

  Until 30 days following the final dose of AZD1775

Study Arms (1)

Wee-1 kinase inhibitor AZD1775

EXPERIMENTAL

To assess the safety of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in patients who have previously completed 1 of the AZD1775 clinical pharmacology studies and not have met any requirements to permanently discontinue treatment with AZD1775.

Drug: Wee-1 kinase inhibitor AZD1775

Interventions

Wee-1 kinase inhibitor AZD1775 DRUG

Patients will receive AZD1775 300 mg orally once daily. Days 1 to 5 and 8 to 12 of a 21 day cycle (ie, 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle). All patients must receive a serotonin receptor 3 (5-HT3) antagonist, ondansetron (Zofran) 8 mg orally/IV or granisetron (Kytril) 1 mg orally/IV prior to each dose of AZD1775. Dexamethasone 4 mg orally/IV will be given with each AZD1775 dose at a minimum on the first day of dosing of AZD1775 of every 5 day dosing period, unless contraindicated or not well-tolerated.

Wee-1 kinase inhibitor AZD1775

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Has read and understands the informed consent form (ICF) and has given written informed consent prior to any study procedures.
• Female or male aged ≥18 years.
• Has completed 1 of the parent AZD1775 clinical pharmacology studies (ie, D6014C00002, D6014C00003, D6014C00004, D6014C00005, or D6014C00006) and in the Investigator's opinion will continue to benefit from treatment with AZD1775. Patients who discontinue early from the parent study will be considered by the Sponsor and treating physician on a case-by-case basis.
• Any prior radiation must have been completed at least 7 days prior to the start of study treatment, and patients must have recovered from any acute effects prior to the start of study treatment.
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 1.
• Baseline laboratory values within 7 days of study treatment initiation in the CA study:
• Absolute neutrophil count (ANC) ≥1500/μL.
• Haemoglobin ≥9 g/dL.
• Platelets ≥100,000/μL.
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 x upper limit of normal (ULN) or ≤5 x ULN if known hepatic metastases.
• Serum bilirubin within normal limits or ≤1.5 x ULN in patients with liver metastases; or total bilirubin ≤3.0 x ULN with direct bilirubin within normal limits in patients with well documented Gilbert's Syndrome.
• Serum creatinine ≤1.5 x ULN, or measured creatinine clearance (CrCl) calculated by Cockcroft-Gault method ≥45 mL/min (confirmation of creatinine clearance is only required when creatinine is \>1.5 x ULN) CrCl (glomerular filtration rate) = (140-age) x (weight/kg) x Fa (72 x serum creatinine mg/dL) where F = 0.85 for females and F = 1 for males.
• Female patients who are of non-childbearing potential and fertile women of childbearing potential (WoCBP) who agree to use adequate contraceptive measures that are in place during screening (or consent), for the duration of the study, and for 1 month after treatment stops; who are not breastfeeding; and who have a negative serum or urine pregnancy test prior to the start of study treatment.
• Male patients must be willing to use barrier contraception (ie, condoms) for the duration of the study and for 3 months after study treatment discontinuation.
• Willingness and ability to comply with the study and the follow-up procedures.

You may not qualify if:

• Involvement in the planning and/or conduct of the study (applies to both AstraZeneca personnel and/or personnel at the study centre).
• Previous enrolment and received study treatment in the present study. Patients can, however, be re-screened if the reason for the screen failure no longer exists.
• Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study.
• Must not have received another systemic anti-cancer therapy in the interval following participation in the AZD1775 clinical pharmacology study and the start of treatment on the CA protocol.
• Not developed any clinical findings suggestive of brain metastasis. Patients continue to be neurological stable and remain off systemic corticosteroids following treatment of known brain metastases.
• Did not tolerate AZD1775 in the parent study in the opinion of the Investigator.
• Where a course of palliative radiotherapy was indicated, the last fraction must have been delivered before the start of study treatment on the CA study.
• Major surgical procedures ≤28 days of beginning study treatment, or minor surgical procedures ≤7 days. No waiting period required following port-a-cath placement or other central venous access placement.
• Grade \>1 toxicities from prior therapy, according to the Common Terminology Criteria for Adverse Events (CTCAE), excluding alopecia or anorexia.
• Continue to be able to swallow oral medication, did not undergo placement of a percutaneous endoscopic gastrostomy tube and did not require total parenteral nutrition.
• Has had prescription or non-prescription drugs or other products known to be sensitive to CYP3A4 substrates or CYP3A4 substrates with a narrow therapeutic index, or to be moderate to strong inhibitors/inducers of CYP3A4 between the parent study and entry into this CA study. Co administration of aprepitant or fosaprepitant during this study is prohibited.
• Has consumed herbal preparations between the parent study and entry into this CA study.
• Has consumed grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges between the parent study and entry into the CA study.
• Any known hypersensitivity or contraindication to AZD1775 or to the components thereof.
• Any of the following cardiac diseases currently or within the last 6 months as defined by the New York Heart Association ≥Class 2:

Sponsors & Collaborators

• AstraZeneca: lead
• Quintiles, Inc.: collaborator

Study Sites (14)

Research Site

Bingham Farms, Michigan, 48025, United States

Location

Research Site

Detroit, Michigan, 48202, United States

Location

Research Site

Lebanon, New Hampshire, 03756, United States

Location

Research Site

Cincinnati, Ohio, 45229, United States

Location

Research Site

Providence, Rhode Island, 02903, United States

Location

Research Site

Greenville, South Carolina, 29605, United States

Location

Research Site

Dallas, Texas, 75251, United States

Location

Research Site

Bordeaux, 33075, France

Location

Research Site

Saint-Herblain, 44805, France

Location

Research Site

Amsterdam, 1066 CX, Netherlands

Location

Research Site

Amsterdam, 1081 HV, Netherlands

Location

Research Site

Maastricht, 6202 AZ, Netherlands

Location

Research Site

Glasgow, G12 0YN, United Kingdom

Location

Research Site

Manchester, M20 4BX, United Kingdom

Location

Study Officials

• Lone Ottesen, MD

  AstraZeneca

  STUDY DIRECTOR

• Henk Verheul, MD

  Amsterdam UMC, location VUmc

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 13, 2017
• First Posted: October 18, 2017
• Study Start: October 27, 2017
• Primary Completion: May 17, 2019
• Study Completion: May 17, 2019
• Last Updated: June 24, 2019

Record last verified: 2019-06

Data Sharing

• IPD Sharing: Will not share

Locations

NL (3); FR (2); US (7); GB (2)